The GCC Innovative Drug Discovery and Development (IDDD) Consortium would like to invite you to register to audit our Foundations of Cancer Therapeutics Course: Commercialization & Careers that will take place from 10 am – 3 pm August 12-16.  This year’s 1-week course will focus on therapeutics commercialization and a variety of careers necessary for commercialization. Note that while cancer therapeutics will be highlighted, the majority of what we will cover is disease-agnostic, so all with an interest in drug development and commercialization are invited to join.

We invite all postdocs to apply to be considered for a limited number of 2024 IDDD Fellow positions. IDDD Fellows will be able to attend the Foundations of Cancer Therapeutics Commercialization and Careers course in person as well as participate in other exclusive networking and educational components of the IDDD program and will receive a certificate at the end of the one-year (Aug. 12, 2024 – Aug. 11, 2025) program. If you would like to be considered for an IDDD Fellow position, please send your CV along with a brief statement of your research interests and  why you think the program would be beneficial to your career goals to GCCResearch@rice.edu.  Please also copy your mentor with a statement confirming that they have approved your in-person attendance of the course and participation in the program.  The application deadline is August 1, and those awarded Fellow positions will be notified by August 5. Note that there are a limited number of slots available.

Confirmed speakers include Deepavali Chakravarti, Texas Medical Center Innovation; Tinashe Chandauka, Texas Medical Center Innovation; Diana Chow, University of Houston;  Dillon Fritz, Gulf Coast Consortia REACH; Jean Gilbert, MD Anderson Cancer Center; Michael Heffernan, Fannin Innovation; Sarah Hein, March Biosciences; Larry Hope, MD Anderson Cancer Center; Phil Jones, MD Anderson Cancer Center; Jeff Larson, Tvardi; Sahar Paz, Own Your Own Voice Strategy; Emily Reiser, TMC Innovation;  Rick Silva, TAMUHSC; Michael Soth, MD Anderson Cancer Center;  Sujatha Sridhar, UT Health Science Center; Patricia Stepp, Rice University; Andrew Strong, Hogan Lovells; Lacey Tezino, Gulf Coast Consortia REACH; Stan Watowich, Ridgeline Therapeutics.